` CALTX (Calliditas Therapeutics AB) vs OMX Stockholm 30 Comparison - Alpha Spread

CALTX
vs
OMX Stockholm 30

Over the past 12 months, CALTX has outperformed OMX Stockholm 30, delivering a return of 0% compared to the OMX Stockholm 30's 5% drop.

Stocks Performance
CALTX vs OMX Stockholm 30

Loading
CALTX
OMX Stockholm 30
Add Stock

Performance Gap
CALTX vs OMX Stockholm 30

Loading
CALTX
OMX Stockholm 30
Difference
www.alphaspread.com

Performance By Year
CALTX vs OMX Stockholm 30

Loading
CALTX
OMX Stockholm 30
Add Stock

Competitors Performance
Calliditas Therapeutics AB vs Peers

OMX Stockholm 30
CALTX
LLY
JNJ
NOVO B
ROG
Add Stock

Calliditas Therapeutics AB
Glance View

Market Cap
12.5B SEK
Industry
Pharmaceuticals

Calliditas Therapeutics AB, a biopharmaceutical company based in Sweden, has carved a niche for itself in the realm of specialty pharmaceuticals, particularly focusing on rare diseases. The company stands out with its dedication to developing novel treatments for orphan conditions that traditionally go under-addressed by larger pharmaceutical entities. Pivotal to its identity, Calliditas leverages its expertise in renal and hepatic diseases, emphasizing precision medicine aimed at improving the lives of patients with severe unmet medical conditions. Their flagship product, Nefecon, is a testament to their approach—designed to treat primary IgA nephropathy, a debilitating kidney disorder. By developing Nefecon with a patient-centric mindset, Calliditas aims to transform the treatment landscape, showcasing its commitment to innovation and regulatory expertise. Revenue generation at Calliditas primarily revolves around the commercialization of its niche therapeutic solutions. The company operates through a well-structured business model that includes strategic partnerships, licensing agreements, and direct market entry. Profits are garnered through successfully translating their clinical research into approved drugs that address critical needs in the healthcare sector. In tandem with developing their portfolio, Calliditas maximizes opportunities within established and emerging markets, ensuring that their highly specialized medicines reach the patients who need them most. This strategic focus not only secures their financial standing but also emphasizes their pivotal role as a pivotal player in rare disease treatment. The resultant revenue stream and successful collaborations underscore Calliditas's capability to marry scientific advancement with commercial viability, ensuring sustainable growth in a competitive pharmaceutical landscape.

CALTX Intrinsic Value
699.55 SEK
Undervaluation 70%
Intrinsic Value
Price
Back to Top